Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis-Reference-Cited by-同舟云学术

Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis

Published:2007-02 Issue:2 Volume:40 Page:471-478
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Zheng Yu,Zhou Hong,Brennan Karen,Blair Julie M.,Modzelewski James R.K.,Seibel Markus J.,Dunstan Colin R.

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference31 articles.

1. Metastatic bone disease: clinical features, pathophysiology and treatment strategies;Coleman;Cancer Treat. Rev.,2001

2. Mechanisms of bone metastasis;Roodman;N. Engl. J. Med.,2004

3. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer 10.1200/JCO.2003.08.017;Hillner;J. Clin. Oncol.,2003

4. Bisphosphonates in breast cancer;Coleman;Ann. Oncol.,2005

5. Reduction in new metastases in breast cancer with adjuvant clodronate treatment;Diel;N. Engl. J. Med.,1998

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RANK pathway in cancer: underlying resistance and therapeutic approaches;Journal of Chemotherapy;2022-10-06

2. In vivo models used in studies of bone metastases;Bone Cancer;2022

3. Osteoonkologie: Knochenmetastasen und Tumortherapie-induzierte Osteoporose;Springer Reference Medizin;2022

4. The Roadmap of RANKL/RANK Pathway in Cancer;Cells;2021-08-04

5. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway;Scientific Reports;2021-06-09